(TRIN) Trinity Capital - Overview
Stock: Term Loans, Equipment Financing, Tech Lending, Life Sciences, Private Credit
| Risk 5d forecast | |
|---|---|
| Volatility | 24.0% |
| Relative Tail Risk | -1.94% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.33 |
| Alpha | -1.66 |
| Character TTM | |
|---|---|
| Beta | 0.585 |
| Beta Downside | 0.655 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.72% |
| CAGR/Max DD | 1.04 |
EPS (Earnings per Share)
Revenue
Description: TRIN Trinity Capital January 20, 2026
Trinity Capital Inc. (NASDAQ: TRIN) is a business-development company (BDC) that originates and invests in term loans, equipment financing, and private-equity-related credit across technology, life-sciences, warehousing, and sponsor-finance segments. Founded in 2019 and headquartered in Phoenix, Arizona (with a satellite office in San Diego), the firm aims to deliver “stable and consistent” returns by tapping the private-credit market, which is largely insulated from public-market volatility.
Key operating metrics (as of the most recent 10-K) show a portfolio of roughly $1.2 billion in assets under management, a weighted-average loan-to-value (LTV) of about 65 %, and an average portfolio yield of 10.3 % annualized. The BDC’s net asset value (NAV) per share has trended upward 12 % year-over-year, reflecting disciplined underwriting and a low default rate (< 2 %).
Sector-level drivers that influence Trinity’s performance include the ongoing “equipment-as-a-service” shift in manufacturing, which fuels demand for flexible leasing structures, and the sustained venture-capital pipeline in life-sciences that creates a pipeline of high-growth, credit-worthy borrowers. Macro-wise, the firm benefits from a steepening credit spread environment when the Fed’s policy rate is high, as investors seek higher-yielding private-credit assets.
For a deeper, data-driven look at TRIN’s valuation and risk profile, you might explore the ValueRay analytics platform’s dedicated TRIN dashboard.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 142.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 31.06 > 1.0 |
| NWC/Revenue: 10.76% < 20% (prev -2.00%; Δ 12.76% < -1%) |
| CFO/TA 0.04 > 3% & CFO 86.5m > Net Income 142.0m |
| Net Debt (1.18b) to EBITDA (162.9m): 7.23 < 3 |
| Current Ratio: 81.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.5m) vs 12m ago 22.43% < -2% |
| Gross Margin: 78.65% > 18% (prev 0.73%; Δ 7792 % > 0.5%) |
| Asset Turnover: 13.33% > 50% (prev 11.29%; Δ 2.05% > 0%) |
| Interest Coverage Ratio: 0.86 > 6 (EBITDA TTM 162.9m / Interest Expense TTM 75.7m) |
Altman Z'' 0.26
| A: 0.01 (Total Current Assets 28.9m - Total Current Liabilities 354.0k) / Total Assets 2.25b |
| B: -0.01 (Retained Earnings -16.9m / Total Assets 2.25b) |
| C: 0.03 (EBIT TTM 64.9m / Avg Total Assets 1.99b) |
| D: -0.01 (Book Value of Equity -16.8m / Total Liabilities 1.25b) |
| Altman-Z'' Score: 0.26 = B |
Beneish M -2.94
| DSRI: 0.85 (Receivables 19.5m/16.9m, Revenue 265.5m/195.8m) |
| GMI: 0.93 (GM 78.65% / 72.76%) |
| AQI: 1.00 (AQ_t 0.98 / AQ_t-1 0.98) |
| SGI: 1.36 (Revenue 265.5m / 195.8m) |
| TATA: 0.02 (NI 142.0m - CFO 86.5m) / TA 2.25b) |
| Beneish M-Score: -2.94 (Cap -4..+1) = A |
What is the price of TRIN shares?
Over the past week, the price has changed by -2.86%, over one month by -6.00%, over three months by +10.87% and over the past year by +9.40%.
Is TRIN a buy, sell or hold?
- StrongBuy: 6
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the TRIN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 16.7 | 11.6% |
| Analysts Target Price | 16.7 | 11.6% |
TRIN Fundamental Data Overview February 21, 2026
P/E Forward = 7.4074
P/S = 4.3079
P/B = 1.1683
P/EG = 5.256
Revenue TTM = 265.5m USD
EBIT TTM = 64.9m USD
EBITDA TTM = 162.9m USD
Long Term Debt = 1.19b USD (estimated: total debt 1.19b - short term 354.0k)
Short Term Debt = 354.0k USD (from shortTermDebt, last quarter)
Debt = 1.19b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.18b USD (from netDebt column, last quarter)
Enterprise Value = 2.33b USD (1.16b + Debt 1.19b - CCE 9.47m)
Interest Coverage Ratio = 0.86 (Ebit TTM 64.9m / Interest Expense TTM 75.7m)
EV/FCF = 27.14x (Enterprise Value 2.33b / FCF TTM 86.0m)
FCF Yield = 3.68% (FCF TTM 86.0m / Enterprise Value 2.33b)
FCF Margin = 32.38% (FCF TTM 86.0m / Revenue TTM 265.5m)
Net Margin = 53.49% (Net Income TTM 142.0m / Revenue TTM 265.5m)
Gross Margin = 78.65% ((Revenue TTM 265.5m - Cost of Revenue TTM 56.7m) / Revenue TTM)
Gross Margin QoQ = 68.32% (prev 76.29%)
Tobins Q-Ratio = 1.04 (Enterprise Value 2.33b / Total Assets 2.25b)
Interest Expense / Debt = 1.77% (Interest Expense 21.0m / Debt 1.19b)
Taxrate = 2.28% (644.0k / 28.3m)
NOPAT = 63.4m (EBIT 64.9m * (1 - 2.28%))
Current Ratio = 81.73 (Total Current Assets 28.9m / Total Current Liabilities 354.0k)
Debt / Equity = 1.19 (Debt 1.19b / totalStockholderEquity, last quarter 998.3m)
Debt / EBITDA = 7.23 (Net Debt 1.18b / EBITDA 162.9m)
Debt / FCF = 13.70 (Net Debt 1.18b / FCF TTM 86.0m)
Total Stockholder Equity = 894.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.13% (Net Income 142.0m / Total Assets 2.25b)
RoE = 15.87% (Net Income TTM 142.0m / Total Stockholder Equity 894.6m)
RoCE = 3.12% (EBIT 64.9m / Capital Employed (Equity 894.6m + L.T.Debt 1.19b))
RoIC = 3.32% (NOPAT 63.4m / Invested Capital 1.91b)
WACC = 4.86% (E(1.16b)/V(2.34b) * Re(8.07%) + D(1.19b)/V(2.34b) * Rd(1.77%) * (1-Tc(0.02)))
Discount Rate = 8.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 21.89%
[DCF Debug] Terminal Value 86.35% ; FCFF base≈86.0m ; Y1≈86.1m ; Y5≈91.3m
Fair Price DCF = 20.42 (EV 2.72b - Net Debt 1.18b = Equity 1.55b / Shares 75.7m; r=5.90% [WACC]; 5y FCF grow -0.45% → 2.90% )
EPS Correlation: 18.94 | EPS CAGR: 8.72% | SUE: -0.04 | # QB: 0
Revenue Correlation: 67.19 | Revenue CAGR: -0.76% | SUE: -1.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.52 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=10
EPS next Year (2026-12-31): EPS=2.09 | Chg30d=+0.001 | Revisions Net=+1 | Growth EPS=+0.3% | Growth Revenue=+18.2%